Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR5A2 | O00482 | 2/20 | 0.83 |
| ▸ | NR5A1 | Q13285 | 2/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.83 |
| ▸ | MAPT | P10636 | 1/20 | 0.74 |
| ▸ | RECQL | P46063 | 1/20 | 0.66 |
| ▸ | FABP3 | P05413 | 1/20 | 0.66 |
| ▸ | SELP | P16109 | 1/20 | 0.61 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.56 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.56 |
| ▸ | PTAFR | P25105 | 1/20 | 0.56 |
| ▸ | HTR1D | P28221 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.56 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.55 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.55 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.55 |
| ▸ | PRKCA | P17252 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31276170 | 1.00 | NR5A2 (0.83) | NR5A2NR5A1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL10498201 | 1.00 | NR5A2 (0.83) | NR5A2NR5A1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL31084795 | 1.00 | NR5A2 (0.83) | NR5A2NR5A1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL4182988 | 1.00 | NR5A2 (0.83) | NR5A2NR5A1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL13735582 | 1.00 | NR5A2 (0.83) | NR5A2NR5A1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL23834444 | 1.00 | NR5A2 (0.83) | NR5A2NR5A1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL3730490 | 1.00 | NR5A2 (0.83) | NR5A2NR5A1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL233018 | 1.00 | NR5A2 (0.83) | NR5A2NR5A1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL25777 | 1.00 | NR5A2 (0.83) | NR5A2NR5A1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL31695681 | 1.00 | NR5A2 (0.83) | NR5A2NR5A1SMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 740 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144803-A1 | LIPOSOMAL FORMULATIONS OF CORTICOSTEROIDS AND USES THEREOF | EDEN OPHTHALMIC PTE LTD. (SG) | 2026-05-28 | — | — | US | claimed |
| EP-4743094-A1 | LIPOSOMAL FORMULATIONS OF CORTICOSTEROIDS AND USES THEREOF | Eden Ophthalmic Pte Ltd. (SG) | 2026-05-20 | — | — | EP | claimed |
| US-12629334-B2 | Lipid emulsions and uses thereof | RESQ PHARMA, INC. (US) | 2026-05-19 | — | — | US | claimed |
| EP-4729635-A2 | DIAGNOSIS AND TREATMENT OF NAFLD AND LIVER FIBROSIS | Beth Israel Deaconess Medical Center, Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4712950-A2 | IONIZABLE AMINE LIPIDS | Intellia Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| EP-4695401-A1 | SYNTHETIC CIRCUITS AND USES THEREOF | Strand Therapeutics Inc. (US) | 2026-02-18 | — | — | EP | claimed |
| EP-4627352-A1 | DIAGNOSIS OF METABOLIC CHANGES OF THE LIVER BY WAY OF METABOLIC ANALYSIS OF ERYTHROCYTES BY MASS SPECTROMETRY | Universitätsklinikum Jena (DE) | 2025-10-08 | — | — | EP | claimed |
| EP-4626400-A1 | NOVEL POLYGLYCEROL-CONJUGATED LIPIDS AND LIPID NANOPARTICLE COMPOSITIONS COMPRISING THE SAME | Generation Bio Co. (US) | 2025-10-08 | — | — | EP | claimed |
| WO-2025123045-A1 | PREDICTIVE AND DIAGNOSTIC SCREENING METHODS FOR ENDOMETRIAL CANCER | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-06-12 | — | — | WO | claimed |
| US-12313634-B2 | Methods for prediction and early detection of diabetes | ZORA BIOSCIENCES OY (FI) | 2025-05-27 | — | — | US | claimed |
| US-20100063135-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-11 | — | — | US | claimed |
| US-20090285881-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-11-19 | — | — | US | claimed |
| WO-2009129385-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-10-22 | — | — | WO | claimed |
| WO-2009129395-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-10-22 | — | — | WO | claimed |
| WO-2008157205-A2 | METHODS AND COMPOSITIONS FOR TREATING URINARY TRACT INFECTIONS USING AGENTS THAT MIMIC OR ELEVATE CYCLIC AMP | DUKE UNIVERSITY (US) | 2008-12-24 | — | — | WO | claimed |
| US-20070014842-A1 | Pharmaceutical liposomal compositions | ID BIOMEDICAL CORPORATION OF QUEBEC C.O.B. AS GLAXOSMITHKLINE BIOLOGICALS NORTH AMERICA (CA) | 2007-01-18 | — | — | US | claimed |
| US-20070014841-A1 | Pharmaceutical compositions | ID BIOMEDICAL CORPORATION OF QUEBEC C.O.B. AS GLAXOSMITHKLINE BIOLOGICALS NORTH AMERICA (CA) | 2007-01-18 | — | — | US | claimed |
| EP-1536831-A2 | PHARMACEUTICAL LIPOSOMAL COMPOSITIONS CONTAINING N. MENINGITIDIS DERIVED POLYPEPTIDES OR POLYNUCLEOTIDES | ID Biomedical Corporation (CA) | 2005-06-08 | — | — | EP | claimed |
| US-20040132652-A1 | Pharmaceutical compositions | SHIRE BIOCHEM INC. (CA) | 2004-07-08 | — | — | US | claimed |
| WO-2004019976-A2 | PHARMACEUTICAL LIPOSOMAL COMPOSITIONS CONTAINING N. MENINGITIDIS DERIVED POLYPEPTIDES OR POLYNUCLEOTIDES | ID BIOMEDICAL CORPORATION (CA) | 2004-03-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063135-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | LIPA, LIPG, LIPC | NR5A2 3037/4885NR5A1 1639/4885SMN1; SMN2 2289/4885 |
| US-20260144803-A1 | LIPOSOMAL FORMULATIONS OF CORTICOSTEROIDS AND USES THEREOF | STARD3, STARD7, PHOSPHO1 | NR5A2 912/4885NR5A1 167/4885SMN1; SMN2 3764/4885 |
| US-20070014842-A1 | Pharmaceutical liposomal compositions | NGLY1, PHOSPHO1, LPXN | NR5A2 2921/4885NR5A1 3363/4885SMN1; SMN2 1933/4885 |
| US-12629334-B2 | Lipid emulsions and uses thereof | PLTP, PNLIP, PHOSPHO1 | NR5A2 4596/4885NR5A1 4240/4885SMN1; SMN2 1225/4885 |
| US-20090285881-A1 | CATIONIC LIPIDS AND USES THEREOF | LIPA, SGMS2, SGMS1 | NR5A2 3864/4885NR5A1 3780/4885SMN1; SMN2 2586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.